Introduction: The Comprehensive in vitro Proarrhythmia Assay (CiPA) is intended to address the misidentification of drug-associated torsade de pointes risk based solely on hERG and QT data. This new paradigm will consist of four interrelated components, one of which is a panel consisting of six ion channels whose currents are important in both depolarization and repolarization of the cardiac action potential. This study examined the effects of 30 clinical drugs on these ion channels. Methods: Ion currents were evaluated in expression systems using the manual whole cell patch clamp technique. Currents were elicited using either a ventricular action potential waveform or step-ramp voltage protocols. Results: Of the seven ion currents studied, hERG was the most often blocked current followed by Nav1.5-late, and Cav1.2. Using a 20% reduction in current amplitude as an arbitrary maker, at a free plasma C max concentration, no drug tested blocked Nav1.5-peak, KvLQT1/mink, Kir2.1 and Kv4.3 by that amount. At a 3x free plasma C max , every current except Kir2.1 had at least one drug reduce current amplitude by at least 20%. Discussion: This is the first study of its kind to examine the effects of 30 clinical drugs against the seven ion currents currently proposed to makeup the CiPA ion channel panel. The results indicate the importance of drug-induced block of hERG, Nav1.5-late and Cav1.2 at clinically relevant concentrations, with low risk torsade drugs having equal or greater Nav1.5-late or Cav1.2 block compared to hERG block. In addition, the results of this study provide data which can be used to test the ability of various in silico models to predict drug-induced arrhythmias.
Introduction
The Comprehensive in vitro Proarrhythmia Assay (CiPA) is intended to address the misidentification of drug-associated torsade de pointes risk based solely on hERG and QT data (Sager, Gintant, Turner, et al., 2014) . This new paradigm will consist of four interrelated components: an ion channel panel, in silico action potential reconstructions of the ion channel panel activity, and verification of results in stem cell derived human cardiomyocytes and in human phase 1 ECGs. To this end, the Safety Pharmacology Society organized the Ion Channel Working Group (ICWG) consisting of representatives from the pharmaceutical industry, regulatory agencies, contract research organizations, and academia. The ICWG was tasked with selecting the ion channels to be tested (Fermini, Hancox, Abi-Gerges, et al., 2016) . The ion channel panel decided upon consists of six ion channels whose currents are important in both depolarization and repolarization of the cardiac action potential (I Kr , I Na , I Ca , I Ks , I to and I K1 ) (Fermini et al., 2016) .
These currents contribute to all components of the cardiac action potential (Grant, 2009; Nerbonne & Kass, 2005) . Starting from a resting membrane potential, determined largely by the inwardly rectifying potassium current (I K1 ), the upstroke or V max of the cardiac action potential is due to an influx of Na + ions through the Na channel (I Na -peak).
This is followed by a rapid phase of repolarization or phase 1 due to the efflux of K + ions through the transient outward potassium current (I to ). Following this is the plateau of the cardiac action potential carried by an influx of Ca ++ ions through the L-type Ca channel (I Ca ) and to a smaller extent through an influx of Na + ions through the Na channel.
This Na current flowing during the plateau period is commonly referred to as the late Na current (I Na -late). Blockade of both the L-type Ca current and I Na -late have been associated with a reduction in QTc prolongation and torsade even in the presence of hERG block (Belardinelli et al., 2013; Gintant, Su, Martin, & Cox, 2006; Johannesen et al., 2014) . The action potential returns to a resting state via an efflux of K + ions through both the rapid and slow components of the delayed rectifier potassium current (I Kr and I Ks , respectively). For ease of use across industry and academia, these currents are most often recorded in expression systems and not primary cardiac myocytes. Therefore, I K1 , I Na (peak and late), I to , I Ca , I Kr , and I Ks are routinely recorded using cell lines expressing Kir2.1, Nav1.5, Kv4.3, Cav1.2, hERG, and KvLQT1/mink, respectively.
The purpose of the present study was to evaluate the ion current blocking profile of thirty clinical drugs against these expressed ion channels using the manual patch clamp technique and to provide insight into which ion currents are more frequently blocked at concentrations corresponding to free plasma C max and multiples thereof. This could have preliminary implications for whether all 7 ion channel currents should be assessed for every drug under CiPA. In addition, the ion channel blocking patterns of drugs that have high, intermediate and low torsade de pointes risk is compared. Furthermore, the results presented in this study can be used to evaluate various in silico action potential models for their ability to define and categorize the arrthymogenic risk of the drugs tested here.
Methods
The cloned equivalent of the human I Kr (hERG-HEK), IKs (KvLQT1/ mink-HEK), I Na (Nav1.5-HEK), I to (Kv4.3-HEK), I K1 (Kir2.1-CHO), and the L-type I Ca (Cav1.2-CHO) were used in this study. Cells were obtained from Cytocentrics Bioscience GmbH (Joachim-Jungius-Straße 9, 18059 Rostock, Germany).
Internal and external recording solutions
The external (bath) solution for hERG, KvLQT1/minK, Kir2.1, Kv4.3 had a composition of in mM: NaCl 137, KCl 4, MgCl 2 1, CaCl 2 1.8, HEPES 10, dextrose 11 with a pH of 7.4 (NaOH). The internal (pipette) solution had a composition of (in mM): KCl 130, MgCl 2 1, NaCl 7, HEPES 5, EGTA 5 with a pH of 7.2 (KOH). The external solution for Cav1.2 and Nav1.5 had a composition of in mM: NaCl 137, KCl 4, MgCl 2 1, CaCl 2 1.8, HEPES 10, dextrose 11 with a pH of 7.4 (NaOH). The internal solution was (in mM): CsCl 130, MgCl 2 1, NaCl 7, HEPES 5, EGTA 5 with a pH of 7.2 (CsOH). In Cav1.2 experiments, 1.8 mM CaCl 2 was replaced with 4mM BaCl 2 . Chemicals were obtained from either Sigma-Aldrich (MA) or Fisher Scientific (PA).
Test compounds
Test compounds were obtained from either Tocris Biosciences (MN) (dofetilide, quinidine, ranolazine, verapamil, mexiletine, lidocaine, diltiazem) or Sigma-Aldrich (MA) (all others). Compounds were dissolved in either de-ionized H 2 O or DMSO to create master stock solutions. This stock was subdivided into aliquots which were stored frozen until use. Dilutions of the master stock to create the final test concentrations were performed on the day of experimentation. Compounds were tested at four different concentrations (free plasma C max and 3 multiples of C max (see Table 1 ).
Data acquisition and analysis
Experiments (n = 3-6) were performed at 36 ± 1°C with the exception of Kv4.3 which was performed at 22 ± 1°C. This was done because separation of the Kv4.3 ionic current from the capacitive current could not be done at 36°C, making it impossible to measure current amplitude accurately. Currents were measured using the whole-cell variant of the patch clamp method as previously described (Crumb, Pigott, & Clarkson, 1995) . Glass pipettes were pulled from borosilicate glass by a horizontal puller (Sutter Instruments, USA). Pipette tip resistance was approximately 1 to 2 MΩ when filled with internal solutions. Series resistance was compensated electronically by approximately 60-80%. An Axopatch 1-B amplifier (Axon Instruments, Foster City, CA) was used for whole-cell voltage clamping. Creation of voltage clamp pulses and data acquisition was controlled by a computer running pClamp software (ver 9.2 Axon Instruments). After rupture of the cell membrane (entering whole-cell mode), current kinetics and amplitudes were allowed to stabilize (typically 3-5 min) as the cell was dialyzed with internal solution and the voltage protocol was applied every 10 s (applied at 0.1 Hz). For Cav1.2 and KvLQT1/mink, currents which tend to exhibit more current rundown, the reduction in current amplitude typically occurred within the first minutes after rupture of the cell membrane. If present (N 20% current reduction), these cells were discarded. Only cells with a stable ionic current and stable holding current were used. The voltage protocols used to record the various currents are given in Panel A of Figs. 1-7. A ventricular action potential waveform was used to elicit hERG, Cav1.2, and KvLQT1/mink (kindly provided by Dr. Gail Robertson, University of Wisconsin). For Nav1.5 (peak and late), Kv4.3 and Kir2.1, the voltage protocols used were those proposed by the ICWG. For measurement of Nav1.5-late, current was elicited by the addition of 50 μM veratridine to the external solution. Drug was applied to the bath solution via a rapid perfusion apparatus. Not all four concentrations were examined in every cell. Some currents were also examined for drug blocking effects by applying the pulse protocol every 1 s (applied at 1 Hz). The drugs examined (quinidine, moxifloxacin, dofetilide, ranolazine, diltiazem, and verapamil) were those evaluated in recent clinical studies (Johannesen, Vicente, Mason, et al., 2014 . Not all of these drugs were examined for every current at 1 Hz.
Time-control experiments were performed for each current in which cells were exposed to non-drug containing external solution spiked with 0.1% DMSO for 5-8 min (the time period of a typical experiment).
Data are presented as % reduction of current amplitude. This was measured as current reduction after an apparent steady-state effect has been reached in the presence of drug (or vehicle) relative to current amplitude before drug (or vehicle) was introduced (control). Each cell served as its own control. When possible (greater than 50% block in any cell was observed), a nonlinear curve-fitting routine was utilized to fit a three-parameter Hill equation to the results using R version 
where Vmax = 100, k, and n are unconstrained variables. Data tables with individual values for each drug are given in Supplement 1.
Results

hERG (I Kr )
The hERG current is an important current in repolarization of the myocardium and the most common target for QT prolonging drugs. The effect of drugs on the amplitude of the hERG current was assessed using the protocol shown in Fig. 1A . This voltage protocol elicited a current that peaked at voltages corresponding to the repolarization phase of the action potential (Fig. 1B) . As an example, addition of QT prolonging drug sotalol produced a concentration-dependent reduction of hERG current with an IC 50 value of 86.4 μM (Fig. 1C) . Fig. 1D plots the percent hERG block associated with all 30 drugs at the free plasma C max . As indicated, drugs commonly associated with QT prolongation produce a marked blockade of hERG current at therapeutic concentrations (e.g. quinidine, dofetilide). To assess the rate-dependence of hERG block, a subset of 6 drugs were evaluated at near IC 50 concentrations by applying the voltage protocol every second. The block produced by quinidine (0.3 μM), moxifloxacin (70 μM), dofetilide (2 nM), ranolazine (6.9 μM), diltiazem (12.5 μM), and verapamil (0.5 μM) at 1 Hz was less than 6% greater than that observed at 0.1 Hz, suggesting a lack of rate-dependent block of hERG current by these tested drugs at these rates. This however does not exclude the possibility that ratedependent changes may be observed with other drugs. Time-control experiments indicate that over the time course of a typical experiment (5-6 min) hERG current amplitude was reduced by 2.5 ± 1.9% (data not shown; n = 6).
3.2. Nav1.5-late (I Na -late)
The Na current flowing during the plateau of the action potential has been shown to contribute to action potential duration (APD). This current has been designated I Na -late. Blockade of I Na -late can shorten APD and QT, attenuate prolongations resulting from hERG block and prevent early after depolarizations. At 37°C, Nav1.5 normally decays rapidly and within approximately 3 ms there is little measurable current remaining (Supplemental Figure 1A) . In order to observe Nav1.5-late, the normal process of channel inactivation must be altered. This is typically done with a toxin such as ATX-II or veratridine (Belardinelli et al., 2013; Chevalier, Amuzescu, Gawali, et al., 2014) . In the present experiments, Nav1.5-late was elicited by the application of 50 μM veratridine to the bath solution. In the presence of veratridine, I Na decays much more slowly and a measurable late current is easily observed (Supplemental . Furthermore, when measuring Nav1.5-late current 40 ms after initiation of a step to −15 mV, there is a clear distinction between the peak and late components of Nav1.5 (Supplemental Figure 1B ). As indicated in Fig. 2 , the most well described blocker of I Na -late, ranolazine, concentration-dependently blocked Nav1.5-late with an IC 50 of 7.9μM. At free C max plasma concentrations, 5 drugs (quinine, ranolazine, flecainide, lidocaine and mexiletine) exhibited approximately a 10% or greater blockade of Nav1.5-late and between approximately 25% to 50% blockade at 3x C max (Fig. 2D) . To further verify that the current being measured 40 ms after the start of a pulse to −15 mV was indeed Nav1.5-late, for 3 drugs the current amplitude was measured at − 15 mV during the voltage ramp which is 342 ms after pulse initiation (see Fig. 2A ). The IC 50 values for ranolazine, lidocaine, and mexiletine were 10.1 μM, 8.4 μM, and 8.4 μM when measured 342 ms after pulse initiation, respectively. This compares very well with values obtained 40 ms after pulse initiation (ranolazine: 7.9 μM, lidocaine: 10.8 μM, mexiletine: 8.9 μM). Time-control experiments of Nav1.5-late showed little change in current amplitude (0.4 ± 0.3% reduction, n = 8).
Cav1.2 (I CaL )
Cav1.2, which encodes the L-type Ca ++ channel, plays a critical role in the contraction of the myocardium and block of this current can attenuate the APD and QT prolonging effects of hERG blocking drugs. Initial experiments in which Cav1.2 was measured using 1.8mM Ca ++ indicated that a small amplitude current (typically b200 pA), was elicited by the action potential waveform shown in Supplement Figure 2 . For the purposes of the experiments described here, Ca ++ was replaced with Ba ++ to increase current amplitude and more easily allow pharmacological evaluation. This does not suggest that Ba ++ will be chosen as the charge carrier in the final CiPA assay. Using Ba ++ as a charge carrier, the inward current recorded was blocked by verapamil and exhibited a characteristic Cav1.2 current voltage (I-V) relationship (Supplement Figure 2 ). An example of the pharmacology of this channel is shown in Fig. 3 . As illustrated, diltiazem blocked Cav1.2 with an IC 50 of 112nM. Fig. 3D illustrates that classic L-type Ca ++ channel blockers such as diltiazem and verapamil block Cav1.2 by approximately 20% or more at free plasma C max . The ratedependence (1 Hz) of Cav1.2 block was determined for the 2 L-type calcium channel blocking drugs, verapamil (150 nM) and diltiazem (150 nM). In the absence of drug, pacing at 1 Hz reduced Cav1.2 current amplitude by 29.2 ± 6.7% (n = 6). In the presence of either diltiazem or verapamil, there was no additional relative block observed at a pacing rate of 1 Hz as compared to 0.1 Hz (diltiazem: 1.8 ± 1.1%, verapamil: 0 ± 0%, n = 3). Time-control experiments indicate that over the time course of a typical experiment Cav1.2 current amplitude was reduced by 2.0 ± 1.2% (n = 4). Voltage protocol used to elicit current at 36 ± 1°C. Arrow indicates where current was measured. B. Example of the effects of ranolazine on Nav1.5-late current. Only current during the step to −15 mV is shown. Current was measured at the end of the step to −15 mV. C. Concentration-response relationship for ranolazine block of Nav1.5-late. Fit equation is given in Section 2. D. Amount of Nav1.5-late current block produced by 1, 3X multiples of C max free plasma concentrations for each member of the 30 drug panel (data derived from Tables in Supplement) .
3.4. Nav1.5-peak (I Na -peak)
The rapidly activating component of the sodium current (I Na -peak) plays a critical role in depolarization of cardiac cells and conduction through the myocardium. Nav1.5-peak was recorded at physiologic temperatures (36 ± 1°C) and using 137 mM NaCl in the external solution. To evaluate whether proper voltage control was present under these conditions, I-V relationships were constructed (Supplement Figure 2D ). As indicated, the I-V relationship under the present recording conditions exhibited typical characteristics for well controlled I Na with approximately 25-30 mV between current activation and peak current amplitude and a reversal potential which appears to be very close to the predicted + 79 mV. The I-V relationship after addition of 1 μM tetrodotoxin (TTX) is also shown. Flecainide reduced Nav1.5-peak with an IC 50 of 6.7 μM (Fig. 4) . At C max free plasma concentrations, all of the drugs examined blocked Nav1.5-peak by less than 20% (Fig. 4D) . Time controls were associated with a 2.3 ± 2.3% reduction in Nav1.5-peak (n = 4). Rate-dependence at 1 Hz was determined for ranolazine (23 μM), diltiazem (12.5 μM), lidocaine (10 μM), mexiletine (10 μM), dofetilide (6 nM), verapamil (1 μM), quinidine (5.4 μM), and moxifloxacin (350 μM). There was less than a 10% additional reduction in Nav1.5-peak current when paced at 1 Hz compared to 0.1 Hz for any of the drugs tested (range: 9.7 ± 6.1% for quinidine, 1.2 ± 1.2% for dofetilide, n = 3).
Kv4.3 (I to )
Kv4.3 encodes the transient outward current (I to ) which plays an important role in the rapid phase (phase 1) of action potential repolarization. The current elicited by the voltage protocol shown in Fig. 5A , activated to a peak and then decayed characteristic of the I to recorded in human cardiac cells (Crumb et al., 1995) . As indicated, quinine exhibited concentration-dependent block of Kv4.3 with an IC 50 of 79.3 μM (Fig. 5B & C) . Of the 30 drugs tested, amitriptyline was associated with the greatest amount of Kv4.3 block at free plasma C max concentrations (Fig. 5D) . Time-control experiments showed a 2.3 ± 2.0% reduction (n = 4) in current amplitude.
KvLQT1/mink (I Ks )
KvLQT1/mink encodes the slow component of the delayed rectifier (I Ks ) and plays a role in repolarization of the action potential. Fig. 6B shows an example of KvLQT1/mink block. As indicated, the outward current elicited with the action potential waveform was blocked by quinine with an IC 50 of 37.4 μM (Fig. 6C) . All of the drugs tested blocked KvLQT1/minK by less than 20% at free plasma C max concentrations (Fig. 6D) . The rate-dependence (1 Hz) of KvLQT1/minK block was determined for the 2 blocking drugs, quinidine (5.4 μM) and moxifloxacin (70 μM). With either drug, there was little additional block observed at a pacing rate of 1 Hz as compared to 0.1 Hz (quinidine: 3.8 ± 2.2%, moxifloxacin: 2.6 ± 2.6%, n = 3). Time-control experiments showed an 8.2 ± 0.4% reduction (n = 4) in current amplitude.
Kir2.1 (I K1 )
Kir2.1 encodes the inwardly rectifying potassium current (I K1 ) which helps to set the resting membrane potential in cardiac cells and also contributes to the terminal phase of repolarization of the action potential. Using the voltage protocol shown in Fig. 7A , an inward current is activated that is blocked by chlorpromazine with an IC 50 of 9.3 μM. As illustrated, none of the drugs tested reached a 10% mean blockade of Kir2.1 at free plasma C max concentrations (Fig. 7D) .
Relative incidence of channel block
It is important to gain insight into the relative frequency with which the ion currents which have been suggested to be included in routine screening are affected by these 30 drugs. Taking a 20% reduction in current amplitude as an arbitrary marker, the relative frequency with which the tested ion currents were blocked at any concentration, 1x therapeutic free plasma C max , and 3x C max is shown in Fig. 8 . As expected, hERG is the most frequently blocked current. Nav1.5-late and Cav1.2 were the next most frequently blocked currents with approximately 4 times fewer drugs blocking by 20% or more at 1x and 3x free plasma C max . In contrast, at 1x therapeutic C max , the other currents tested were not blocked by 20% or more by any of the drugs tested. At a 3x multiple of free plasma C max , Kv4.3 was blocked approximately as frequently as Nav1.5-late and Cav1.2, while Nav1.5-peak and KvLQT1/ mink were less frequently blocked. Kir2.1 was not blocked by any drug tested by 20% or more at a 3x multiple of free plasma C max .
Relationship between channel block and arrhythmic risk
The relationship between ion channel block and proarrhythmic risk was examined for a subset of 12 drugs that were rated by the CiPA clinical working group to have low, intermediate or high risk of torsade de pointes. As indicated in Figs. 9 and 10, at both a 1X and a 3X free plasma C max concentration, drugs which are classified as possessing a high risk for pro-arrhythmic events are associated with a large and rather selective block of hERG. In contrast, drugs in the low risk category block either Cav1.2 or Nav1.5-late more so or to a similar degree as hERG at C max . Drugs in the intermediate category block hERG more than other currents but on average are associated with less hERG block at C max than members of the high risk category. Of note, the 40% hERG block shown in Fig. 9 for terfenadine (intermediate risk drug) is associated Fig. 4 . Nav1.5-peak current (I N a-peak) block by the 30 drug panel. A. Voltage protocol used to elicit current at 36 ± 1°C. Arrow indicates where current was measured. B. Example of the effects of flecainide on Nav1.5-peak current. Only current during the step to −15 mV is shown. Peak inward current at the beginning of the step to − 15 mV was measured. C. Concentration-response relationship for flecainide block of Nav1.5-peak. Fit equation is given in Section 2. D. Amount of Nav1.5-peak current block produced by 1, 3X multiples of C max free plasma concentrations for each member of the 30 drug panel (data derived from Tables in Supplement) .
with a C max of 9 nM, a concentration only achieved after metabolic inhibition. However, a more standard C max of 0.3 nM is only associated with 8% hERG block, which could contribute to it being an intermediate versus high risk drug. Other factors such as the kinetics of drug binding to the hERG channel may also be important for differentiating intermediate from high risk drugs.
Discussion
For more than a decade, the cardiac potassium channel hERG has been the focus of both regulatory agencies and drug developers. While this attention has been warranted since drug induced blockade of this channel has been associated with QT prolongation and in rare cases torsade de pointes, the singular focus on this channel has likely led to unwarranted drug attrition and labeling (Stockbridge, Morganroth, Shah, et al., 2013) . In virtually all cases of drug-associated torsade de pointes, the offending drug has been shown to selectively block hERG at relevant plasma concentrations. However, there are drugs which block hERG and despite this activity are associated with little or no QT prolongation and minimal torsade de pointes risk, sometimes due to block of the L-type I Ca (e.g. verapamil) or I Na -late (e.g. ranolazine). In the present study, we observed that the most frequently blocked channels at clinical free C max concentrations were hERG, Nav1.5-late and Cav1.2. While the substantial hit rate for hERG is expected, results from the present study using the manual patch clamp technique under physiologic conditions highlight for the first time that a large number of drugs also block Nav1.5-late and/or Cav1.2 currents, which can reduce the risk of torsade de pointes caused by hERG block (Antoons, Oros, Beelman, et al., 2010; Antzelevitch, Belardinelli, Zygmunt, et al., 2004; Fauchier, Babuty, Autret, et al., 1999; Gintant et al., 2006; January & Riddle, 1989) . This is consistent with the four CiPA low risk drugs in this study having equal or greater Nav1.5-late block (ranolazine and mexiletine) or Cav1.2 block (verapamil, diltiazem) than hERG block, while the intermediate and high risk drugs had greater hERG block than other channels.
Comparison to published data
The results obtained in the present study were compared to previously published results (Kramer, Obejero-Paz, Myatt, et al., 2013) . While many of the drugs evaluated in the present study have published data for various ion channels, the Kramer et al. dataset has many of the drugs tested here and contains data on hERG, Nav1.5-peak, and Cav1.2. As indicated in Table 2 , with few exceptions, the IC 50 values from the 2 studies are very similar. One notable exception is dofetilide, which has an IC 50 value for block of hERG in the present study (2 nM) which is approximately 15 times lower than in the Kramer et al. study (30 nM) . The results obtained from the present study are consistent with the free plasma levels of dofetilide (2.7 nM) associated with an approximately 75 ms increase in QTc (Johannesen et al., 2014) .
The overall similarity in results observed for the 16 drugs in common between the 2 studies is interesting given the very different experimental methods. In the present study, all 3 currents were measured using the manual patch clamp technique at approximately 36°C using either an action potential waveform (hERG, Cav1.2) or a step-pulse (Nav1.5-peak). In the Kramer et al. study, data was obtained using an automated patch clamp platform at room temperature and using step-pulse voltage protocols. These results suggest that for most of the drugs in Table 2 , experimental parameters such as temperature, patch clamp platform, and voltage protocols do not exert a marked effect on IC 50 values. This is somewhat comforting since ultimately the ion channel portion of the CiPA paradigm is expected to be performed via automated patch platforms to accommodate large numbers of compounds and multiple channels. However, there could be greater differences when evaluating drug blocking kinetics.
Four antihypertensive/antianginal drugs with primary effects on the L-type Ca channel (Cav1.2) were evaluated in this study. Two of the four drugs exhibited substantial block of Cav1.2 at free plasma C max concentrations. For instance, diltiazem and verapamil had Cav1.2 IC 50 values of 112 nM and 202 nM (respectively) and free plasma C max values of approximately 128 nM and 45 nM, respectively. In contrast, mibefradil was associated with virtually no block of Cav1.2 at 12 nM and an IC 50 of 652 nM (free plasma C max = 10.6 nM). This is consistent with previous reports in myocytes in which mibefradil exerts a far greater effect on T-type calcium current than on the L-type (Leuranguer, Mangoni, Nargeot, et al., 2001) ). Bepridil showed only a 4.2% reduction in Cav1.2 at 30 nM and an IC 50 of 2.8 μM (free plasma C max = 31.5 nM). In guinea pig ventricular myocytes, bepridil blocks the L-type Ca current with an IC 50 of 500 nM (Yatani, Brown, & Schwartz, 1986) . These results suggest that a characterization of Cav1.2 to define the cardiac effects of L-type Ca ++ channel blockers is an appropriate surrogate for acutely isolated ventricular myocytes.
Frequency of hits on ion currents
To determine the frequency of blockade for the tested ion channel currents, the number of drugs producing a 20% reduction of a given current at any tested concentration was plotted (see Fig. 8 ). The 20% reduction value is an arbitrary number but one commonly referred to in the literature (Crumb, Ekins, Sarazan, et al., 2006; Redfern, Carlsson, Davis, et al., 2003) . The results indicate that hERG was the current most frequently blocked, followed by Nav1.5-late and Cav1.2 each being blocked by greater than 60% of the drugs tested. Kir2.1 was the least frequently blocked current. In addition, the frequency of block at 1x and 3x the free plasma C max was plotted. This showed a very different profile with hERG being blocked by 20% or more by 37% of the drugs and all other currents being blocked by less than 10% of the drugs tested. No drugs blocked Nav1.5-peak, Kv4.3, LvLQT1/mink, or Kir2.1 by 20% or more at a 1x C max concentration. At a 3x C max concentration, hERG was blocked by 70% of the drugs tested whereas all other currents were blocked by 20% or less of the drugs tested. None of the drugs tested blocked Kir2.1 by 20% or more at a 3x C max concentration. 
Stratification of safety risk
Included in the drugs tested were 4 members from each of the CiPA risk categories (high, intermediate and low). These categories were based upon the risk of drug-associated torsade de pointes. We compared ion channel block against all tested ion currents at free plasma C max values of 1x and 3x. This method has been used before on hERG, Cav1.2, and peak Nav1.5 using relative IC 50 values. As indicated in Figs. 9 & 10, members of the high risk category blocked hERG at therapeutic free plasma C max either exclusively or to a much greater extent than any other current examined. In the intermediate category, drug block of hERG was on average less than in the high risk category, supporting a lower risk of torsade de pointes. In the low risk category, the members were associated with a greater or equal block of either Cav1.2 or Nav1.5-late when compared to block of hERG. These results clearly indicate the need for testing drug candidates against a panel of ion channels.
As indicated in Figs. 9 and 10, the ion current blocking profile for some members of the intermediate torsade de pointes risk category is similar to that observed with some members of the high risk category. There are several possible reasons for this including (1) pharmacokinetic or drug interaction properties which may lead to higher plasma concentrations some in patients, (2) differences in risk factors in patient populations receiving each drug, (3) the assignment of drugs into high and intermediate risk categories may be imperfect, and (4) the kinetics of the drug block, particularly for hERG, may make some drugs more proarrhythmic than others. The kinetics of drug binding to the hERG channel and its ability to improve risk stratification is currently being investigated further by the CiPA ion channel and in silico working groups (Fermini et al., 2016) .
In a recent clinical study of quinidine and dofetilide, the free plasma concentrations associated with the approximately 70% and 55% reduction in hERG current amplitude, respectively (see Fig. 9 ) was associated with a79 ms and 74 ms increase in QTc (Johannesen et al., 2014) and Twave morphology changes (Vicente, Johannesen, Mason, et al., 2015) . Furthermore, in the same study, ranolazine was associated with a 12 ms increase in QTc and verapamil was associated with no increase in QTc. The ion channel profile for verapamil supports the clinical results in that there is more block of Cav1.2 than hERG at therapeutic concentrations. The observation of a modest increase in QTc upon exposure to therapeutic concentrations of ranolazine suggests that the hERG block induced QTc prolongation is not completely counteracted by block of Nav1.5-late, but is enough to counteract torsade de pointes risk. However, the QTc prolongation associated with ranolazine has a specific 'signature' that involves T peak -T end prolongation without prolongation of the heart rate corrected J-T peak (J-T peak c) interval (Johannesen et al., 2014) . Additional recent clinical study suggests that the J-T peak c interval is a better biomarker (than QTc) in assessing the balance of inward and outward current block and predictor of low torsade risk drugs (Johannesen et al., 2014) . The CiPA clinical phase 1 ECG working group is expanding this analysis to additional drugs and will propose a framework for potential implementation of this new approach at an April 2016 Cardiac Safety Research Consortium meeting.
Limitations
The following are limitations of the present study. 1). The action potential waveform used was recorded from rabbit, and not human, ventricle. While this waveform has been used previously to characterize hERG (Zhou, Gong, Ye, et al., 1998) , we are cognizant that the data may be more relevant if a human ventricular AP was used instead. 2). Kv4.3 current was measured at room temperature and not physiologic temperature, as with the other ion currents. This was done to allow separation of the capacitive transient from peak Kv4.3 current. It is not known if the Kv4.3-drug interaction, for the drugs tested here, is temperature sensitive. 3). The drug effects on ion currents were tested at a pacing rate of 0.1 Hz. This pacing rate was chosen because it is often used in the literature and it represents a common pacing rate for all currents tested that was not associated with significant rundown. However, currents were evaluated against some drugs at a pacing rate of 1 Hz, which showed limited differences from the 0.1 Hz data. 4). Nav1.5-late was elicited by the use of veratridine. Although sodium channel inactivation modifiers such as veratridine and ATX-II are commonly used to increase the amplitude of late-I Na , it is not known if they may interfere/alter the effects of late I Na blockers. 5). In the present study, drugeffects were not "washed out" to provide insight into whether the reduction in current amplitude was due to actual drug block or current rundown. However, time controls suggest that any reduction in current amplitude was due primarily to drug-related ion current block. Furthermore, not all drug blocking effects, particularly at higher concentrations, are able to be "washed out". 6). The Ca ++ and Mg ++ in the external solution can have blocking effects on hERG current (Ho, Kim, Lee, & Earm, 1998; Po, Wang, Yang, et al., 1999) . This may make it difficult in calculating the actual drug-hERG current blocking effects. However, the ion concentrations were physiologic and it is unlikely that Ca ++ and Mg ++ will be absent in the plasma of individuals taking these drugs.
The in silico and ion channel working group for the CiPA initiative are currently studying voltage clamp protocols that model dynamic drug-ion channel interactions for hERG, and potentially for other channels (Fermini et al., 2016) . Thus, final CiPA voltage clamp protocols for hERG, and potentially other channels, may differ substantially from those used in this study. However, a critical first step is to identify IC 50 values or the maximal percent block at clinically relevant drug concentrations to determine which channels are the most important channels to be assessed under CiPA. While this ion channel data could also be entered into in silico models, such as the O'Hara-Rudy model (O'Hara, Virág, Varró, & Rudy, 2011), we elected to not do that here because it is beyond the scope of this manuscript and because the in silico proarrhythmia metrics have not been finalized. Rapidly publishing this data will allow any investigators to use it for in silico modeling. Finally, drugs were selected with a stratified risk of torsade de pointes, existing clinical ECG data, and with a range of ion channel effects. However, the hit rates for block of the different channels are only reflective of the 30 drugs in this study.
Conclusion
This is the first study of its kind to examine the effects of 30 clinical drugs against the 7 ion channel currents currently proposed to makeup the CiPA ion channel panel. The results of the present study highlight the importance of drug-induced block of hERG, Nav1.5-late and Cav1.2 at clinically relevant concentrations. These were the most frequently blocked currents and are likely the most important in terms of increased risk for torsade de pointes (blocking hERG) vs. decreasing risk (blocking Nav1.5-late and/or Cav1.2). This was consistent with the 12 CiPA drugs, where high and intermediate risk drugs had greater hERG block than other channels, while low risk drugs had equivalent or greater Nav1.5 block (ranolazine and mexiletine) or Cav1.2 block (verapamil, diltiazem) than hERG block. Nav1.5-peak block was the next most commonly blocked channel, and its importance in conduction and potential for use-dependent block that was not thoroughly assessed here, suggest that it also is important to be assessed under CiPA. Based upon the 30 drugs tested in this study, the less frequent hit rates for Kv4.3, KvLQT1/mink and Kir2.1 suggest that these channels may be less critical for assessment of all drugs under CiPA. This should be further evaluated with consideration of potential false positive hit rates along with the impact of block of these channels has on proarrhythmic risk in the CiPA in silico action potential model.
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